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5-(4-(Benzyloxy)substituted phenyl)-3-((phenylamino)methyl)-1,3,4-oxadiazole-2(3H)-thione as  antifungal agents
“ MOLECULAR SIEVES AND ULTRASOUND ASSISTED SYNTHESIS OF NOVEL1,3,4-
OXADIAZOLE-2-THIONES DERIVATIVES AS POTENTIAL ANTIFUNGAL AGENTS.”
IN THE CATEGORY OF MICROORGANISM, FUNGI ARE CONSIDERED AS THE SPECIAL CLASS OF MICROBES RESPONSIBLE FOR
OPPORTUNISTIC PATHOGENIC INFECTIONS IN HUMANS SPECIES. DUE TO THE SIDE EFFECTS OF COMMERCIALLY AVAILABLE
ANTIFUNGAL DRUGS AND THE EMERGENCE OF NEW DRUG RESISTANT FUNGAL SPECIES IN THE PAST FEW YEARS, HAS FORCED THE
RESEARCHERS TO SEARCH FOR NOVEL AND EFFICIENT ANTIFUNGAL DRUG MOLECULES. THE 1,3,4-OXADIAZOLES SCAFFOLD IS
ASSOCIATED WITH DIVERSE BIOLOGICAL ACTIVITIES. THE MULTIPURPOSE USE OF THEMANNICH BASES IN PHARMACEUTICAL
CHEMISTRY PROVOKED US TO PREPARE A NEW SERIES OF1,3,4-OXADIAZOLE MANNICH BASES DERIVATIVES, AS ANTIFUNGAL AGENTS.
HEREIN WE REPORTMOLECULAR SIEVES ANDULTRASOUND ASSISTED SYNTHESIS OF NOVEL SERIES OFMANNICH BASES OF THE5-
SUBSTITUTED 1,3,4-OXADIAZOLE-2-THIONES BY AMINO METHYLATION WITH PARAFORMALDEHYDE AND SUBSTITUTED PRIMARY /
SECONDARY AMINES AND THEIR EVALUATION FOR ANTIFUNGAL ACTIVITY .THE STRUCTURES OF THE NEWLY SYNTHESIZED
COMPOUNDS WERE DETERMINED BY IR, NMR AND MASS SPECTRAL STUDY. THE SYNTHESIZED COMPOUNDS EXHIBITED
INTERESTING MODERATE TO EXCELLENT ANTIFUNGAL ACTIVITY AGAINST CANDIDA ALBICANS (NCIM 3557),CANDIDA
ALBICANS(NCIM3471), CANDIDA GLABRATA(NCIM3237), CRYPTOCOCCUS NEOFORMANS (NCIM 3542),CRYPTOCOCCUS
NEOFORMANS(NCIM 3378),ASPERGILLUS FUMIGATES(NCIM 902), ASPERGILLUS NIGER( NCIM 628) USING FLUCANAZOLE AS A
STANDARD REFERENCE DRUG. THE SYNTHESISED COMPOUNDS6D, 6F ,6G, 6H AND 6J EXHIBITED PROMISING ANTIFUNGAL ACTIVITY
AS FUNGISTAT AGENTS.
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II NTRODUCTION
 The 1,3,4-oxadiazoles scaffold is associated with diverse biological activities such as antifungal[1a-b] antibacterial [2],
antimycobacterial [3], antiHIV [4], anti-hepatitis B virus[5] anticancer [6] anticonvulsant [7], anti-inflammatory [8],
antimalarial [9] analgesic [10] etc. 5-Substituted-1,3,4-oxadiazole-2-thiones represent an important type of compound in the
field of coordination chemistry because of their potential multifunctional donor sites, viz either exocyclic sulfur or endocyclic
nitrogen[11,12] and possess CNS depressant [13]and tyrosinase inhibition [14] property. The multipurpose usage of the
Mannich bases in pharmaceutical chemistry [15,16] provoked us to prepare a newseri s of 1,3,4-oxadiazole based amino
methyl derivatives. The use of ultrasound to endorse chemical reactions is called Sonochemistry. Ultrasonic-
assisted organic synthesis is a green synthetic approach and it is a powerful technique towards the increase in
reaction rate[17,18]. It offers the potential reaction in small time cycles, cheaper reagents and less extreme physical
conditions [19,20]. It can also be considered as important tool for conservation of energy and minimization of
waste as compared to the conventional techniques [21].
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 In the category of microorganism, fungi are considered as the special class of microbes responsible for
opportunistic pathogenic infections in plant, animals and humans species. Commercially available
broad-spectrum antifungal drugs includes fluconazole, itraconazole, miconazole and voriconazole in
which the mechanism of action is on target CYP51 which get inhibited and in turn switch off the
biosynthesis of ergo sterols[22] .
 But the frequent use of these antifungal drugs in immune compromised patients who are undergoing the
NEED  OF STUDY
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long term treatment of broad-spectrum antibiotics may be in cases of HIV infection, grafting surgery or
anticancer therapy [23], has led to the development of resistance fungal strains.
 The emergence of new drug resistant fungal species in the past few years has force the the
researchers around the world to search for novel and efficient antifungal drug molecules. [24,25,26].
OBJECTIVE OF STUDY
 To design and synthesize the novel, 1,3,4-oxadiazole-2-thiones containing MannichBases by using ultrasonic
processor.
 To conduct physicochemical characterization of intermediates and synthesized compounds.
 To confirm the structures of synthesized compounds by analytical and spectral t hniques such as TLC, FT-IR,
ES-MS,1H NMR and13C NMR .
 Antifungal screening of the synthesized compounds against seven selected strains of human pathogenic fungi. viz
Candida albicansNCIM 3557,Candida albicansNCIM3471, Candida glabrataNCIM 3237, Cryptococcus
neoformansNCIM 3542,Cryptococcus neoformansNCIM 3378,AspergillusfumigatusNCIM 902, Aspergillus niger
NCIM 628.
 MATERIALS AND METHODS:
All the chemicals used for synthesis were of Merck, Sigma, Researchl b, Qualigens make and Himedia. The reactions were
carried out by conventional method and Ultrasonic processor (P/No.VCX-500-200) for synthe is. Melting points were
determined in open capillaries using melting point apparatus and are uncorrected. FTIR spectra were recorded by JASCO
FTIR (PS-4000) using KBr powder technique. The1H NMR and13C NMR spectra of synthesized compounds were recorded
on Bruker Avance II 400 NMR Spectrometer at 400 MHz Frequency in deuterated DMSO and CDCl3 and using TMS as







EXPERIMENTAL WORK  & PHYSICAL CONSTANTS DATA
 General procedure for the synthesis of 4-(benzyloxy)benzoate(3):
For the synthesis of4-(benzyloxy) benzoate Equimolar (0.01mol)methyl 4-hydroxybenzoate and chloromethyl
benzene was taken in N,N Dimethyl Formamide (DMF) as solvent and reaction is carried out in K2CO3 in
ultrasonic processor upto 4hr. After that, the solution was poured into ice-water. The precipitate was filtered and










Melting point R f value
3 C15H14O3 242.27 90% 105OC 0.46
Solvent system chosen for Rf value determination was benzene :methanol (8:2).
GENERAL PROCEDURE FOR THE SYNTHESIS OF 4-(BENZYLOXY) BENZOHYDRAZIDE (4):
 For the synthesis of substituted benzohydrazines, a mixture of corresponding esters (20 mmol), 85%
hydrazine hydrate (20 mmol) in ethanol (35 ml) was heated to reflux for 6 h. After that, the solution was











Melting point R f value
4 C15H14N2O2 241 88% 80 0.24
Solvent system chosen for Rf value determination was benzene : methanol (8:2).
 Then equimolar proportion of the substituted benzohydrazine(5 mmol) and potassium hydroxide (5
mmol) were dissolved in 20 mL of 95% ethanol. The mixture was allowed to stir for several minutes at
room temperature and then carbon disulfide(15 mmol) was slowly added drop wise to the reaction
system and the mixture was heated to reflux by using molecular sieves. The residue obtained was
dissolved in water(50 mL) and diluted hydrochloric acid was added to adjust the pH values of the
solution to 5-6. Then the precipitate was collected washed with water for several times and dried and
recrystallized from ethanol. Colour: White M.P.1600C















284 90% 160OC 0.41
Solvent system chosen for Rf value determination was benzene : methanol (8:2).
 1,3,4-Oxadiazole-5-thiones (10 mmol) was dissolved in methanol, then para formaldehyde (15mmol)
and primary/secondary amine (10 mmol) in methanol were added with stirring. The resulting mixture
was kept in ultrasonic processor for 2-4hrs . The precipitated solids were filtered, washed with water and
recrystallized from methanol to yield the title compounds 6a-o (Table 1)
STEP IV: SYNTHESIS OF 1,3,4-OXADIAZOLE-2-THIONES MANNICH BASES:
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Solvent system chosen for Rf value determination was benzene : methanol (8:2).
Derivatives R (Mol. wt) Yield (%) m.p. (oC) Analysis (%) Found 
(calculated)
C     H      N
a 382.48 80 205 62.80           5.80          14.65
(62.76)      ( 5.74)        (14.62)
b 423.92 81 180 62.33            4.28       9.91
(62.28)       ( 4.22 )       ( 9.88)
c 365.41 78 235 59.16           4.1           19.17
(59.11)         ( 4.10)     ( 19.11)
d 364.42 79 240 62.62          4.43           15.37
(62.58)       ( 4.40)       (15.34)
e 468.91 81 218 56.35           3.65          11.95
(56.30)       ( 3.61)      ( 11.92)
f 417.52 79 230 69.04           5.55          10.06
(69.00 )        (5.51)      (10.02)
g 468.37 81 228 56.42            3.87          8.97
Table 1.Characterization data of Mannich bases (6a-o).
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(56.38)        (3.84)      ( 8.93)
h 434.47 90 220 60.82             4.18        12.90
(60.78)       ( 4.13)      (12.86)
i 479.47 82 145 55.11              3.57       14.61
(55.08)         (3.52)      (14.57)
j 383.46 85 200 62.64              5.52       10.96
(62.61)        ( 5.48)      (10.92)
k 389.47 80 80 67.84              4.92       10.79
(67.79)        (4.88)       (10.74)
l 419.13 81 100 65.85              5.05       10.02
(65.81)         ( 5.00)      (10.00)
m 433.48 79 140 63.73              4.42        9.69
(63.67)         (4.39)       ( 9.62)
n 327.40 78 110 62.36               5.23       2.83
(62.31)           (5.19)      (2.79)
o 465.57 79 115 72.23               4.98       9.03
(72.20)           (4.92)      (9.00)
N
In vitro antifungal susceptibility testing were performed by broth micro dilutionmethod
according to the Clinical and Laboratory Standards Institute (CLSI) to find out IC50
concentration and minimum inhibitory concentration (MIC90) of the compounds. The
activities of compounds were checked against human pathogensCandida albicans NCIM
3557,Candida albicans NCIM3471, Candida glabrata NCIM 3237, Cryptococcus
ANTIFUNGAL SCREENING
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neoformans NCIM 3542,Cryptococcus neoformans NCIM 3378,Aspergillus fumigatus
NCIM 902,Aspergillus niger NCIM 628.
PROTOCOL FOR ANTIFUNGAL ACTIVITY
 Stock of each compounds were prepared in DMSO at concentration of 12800 µg/ml.
Stocks were serially diluted two fold in micro titer plate and 4µl of this is used for
assay to get a final concentration in the range of 256-2 µg/ml.
 Spores of the filamentous fungi (~2x104 spores/ml) and yeast cells freshly grown in
YPG broth in logarithmicphase(~2x103cfu/ml) weresuspendedin the RPMI 1640
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medium and 196µl from these were inoculated in the wells of the plate.
 The microtitre plate were incubated for 24-48hr.
 Growth was determined by visual observation and measuring absorbance at 600 nm
using micro titre plate reader.
 The IC50 was defined as the concentration exhibiting 50% inhibitionof the growth as
compared to the growth of control. Whereas MIC90 was the concentration






























6a 64 49.6 64 64 64 >256 27.7
6b 128 67.12 59.6 77.5 >128 24.2 24.1
6c 21.6 108 53.6 108.9 196.5 11.2 93
6d 68 159 65.6 128 >128 6 130
6e 54.4 44.6 24.5 64 14.21 25.8 47
Table 2: Representation of IC50 Antifungal screening of 6(a-o)
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6f 16 84.9 5.4 >256 90 - >256
6g 62 107.6 256 76.8 94.7 4 >256
6h 55.3 57.4 64 47.6 66.6 16 18.61
6i 23.3 80.6 40.3 256 93.5 24.6 >256
6j 38.4 31.5 56.6 192 39 8 128
6k 150 53.3 36.2 64.2 146.6 35.1 22.9
6l 115 95.3 42.5 49.7 145.8 81 73.2
6m 91.5 49.7 78.6 62.5 54.6 87.4 84.8
6n 30.3 43 48.8 47.5 105.6 81.5 56.9
6o 95 28.1 50.7 42.7 156.5 76.1 70.5
Fluconazole 0.12 0.11 9.4 16 4 64 46


























6a >256 >64 64 >256 >256 >256 >64
6b >256 128 128 >256 >256 128 >256
6c 128 128 128 >256 >256 128 >256
6d >256 >256 >128 >256 >256 256 >256
6e 64 64 64 256 >256 128 256
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6f 64 256 8 >256 >256 256 256
6g 128 256 256 256 >256 256 256
6h 128 >256 256 >256 >256 256 >256
6i 32 128 64 256 256 256 128
6j 128 256 256 256 >256 >256 256
6k >256 >256 >256 >256 >256 >256 >256
6l >256 >256 >256 >256 >256 >256 >256
6m >256 >256 >256 >256 >256 >256 >256
6n >256 >256 >256 >256 >256 >256 >256
6o 128 32 128 64 >256 128 128
Fluconazole 0.25 0.25 16 32 8 >256 >256
1H Spectra:
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Sr. No. δ   Values (ppm) Multiplicity No. of proton Group
1 3.8 s 1H N-H
2 5.1-5.2 m 2H Hd
3 7.0-7.1 m 2H Hc
4 7.3-7.4 m 5H Phenyl ring (Ha)
5 7.8-7.9 s 2H -CH2 (Hb)
Mass Spectra:
C-3 #114 RT: 0.51 AV: 1 NL: 1.86E8


























C15 H13 O2 N2 S= 285.0692
0.3895 ppm

























































D-5-H #162 RT: 0.72 AV: 1 NL: 6.01E7





























C22 H18 O4 N4 Na S= 457.0941
0.8433 ppm
Mass fragmentation





































 Among the synthesised compounds
6g(4µg/ml),6d(6µg/ml),6j(8µg/ml),6c(11.2µg/ml),6h(16µg/ml),6b(24.2µg/ml),6i(24.6µg/
ml),6e(25.8µg/ml) & 6k(35.1µg/ml) givexcellent activity against the strainAspergillus
fumigatus (NCIM 902) for which the standard drug fluconazole requiredis (64 µg/ml).
 Similarly compounds6h(18.61µg/ml),6k(22.9µg/ml),6b(24.1µg/ml) & 6a(27.7µg/ml) gives
excellent activity against the Aspergillus niger.(NCIM 628),whereas6e(47µg/ml) give
RESULTS  AND  DISCUSSION:
good activity against the same strain, the standard drug fluconazole required is (46 µg/ml).
 Compound 6f (5.4 µg/ml) givesexcellentactivity againstCandida glabrata(NCIM 3237)
and 6e(24.5µg/ml)showgood activity, the standard drug fluconazole required is (9.4
µg/ml).




Fifteen novel derivatives of5-(4-(benzyloxy)substituted phenyl)-3-((phenylamino)methyl)-1,3,4-
oxadiazole-2(3H)-thionewere successfully synthesized underultrasound irradiation giving better
yield of 75-95% and in shorter duration of 2-4 hrs in contrast to conventional reactions which
requires refluxing of 10-12 hrs. . The structures of all the compounds were confirmed by recording
their 1H NMR, 13C NMR, Mass and IR spectra. All the newly synthesized compounds were screened for
their in vitro antifungal properties. The compounds were found to be fungi static. Among the screened
samples, nearly nine derivatives exhibited excellent antifu gal activity againstAspergillus fumigatus
(NCIM 902), fluconazolewas used as standarddrug, (64 µg/ml).The excellent antifungal activity
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exhibited by the following compounds may be due to the presence of various electron withdrawing
groups. All the mentioned derivatives give excellent activity, such as 6g(4µg/ml) having bromine at
para position of phenyl act as strong withdrawing groups is found to be the most potent,6d(6µg/ml)
having imidazole,6j(8µg/ml) morpholine,6c(11.2µg/ml) having triazole,6h(16µg/ml) having nitro at
para position of phenyl and6b(24.2µg/ml) having para substituted chlorophenyl,6i(24.6µg/ml) show
two nitro phenyl group at ortho and para position,6e(25.8µg/ml) ortho nitro and para chloro phenyl and
6k(35.1µg/ml) having un substituted phenyl.
 Other compounds which exhibited excellent antifungal activity
6h(18.61µg/ml),6k(22.9µg/ml),6b(24.1µg/ml) & 6a(27.7µg/ml) having piperazine as a
substituent,6e(47µg/ml) againstAspergillus niger.(NCIM 628) and fluconazole, standard drug
required is (46µg/ml). Some compounds exhibited excellent to good activityagainstCandida
globrata(NCIM3237) when comparedwith the same standarddrug fluconazole(9.4 µg/ml)
such as6f (5.4µg/ml) ortho and para di substituted toluyl;6e(24.5µg/ml)shows good activity .
 With these excellent result here we can conclude that5-(4-(benzyloxy)substituted phenyl)-3-
((phenylamino)methyl)-1,3,4-oxadiazole- 2(3H)-thionederivatives can act as a potent scaffold
to develop newer drugs possessing antifungal activity. Thefinal derivatives possessing electron
withdrawing groups on phenyl ring at position 3 of nitrogen of 1,3,4-Oxadiazole-2-thiones ring
are acting as more potent compounds and exhibit excellent antifungal activity .
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